0512-67998889(Suzhou)
18051093220(Shenzhen)
In the latest update, the National Steering Committee Office for High-tech Enterprise Certification has released the "Third Batch of 2024 High-tech Enterprise Certification Filing Public Notice List" as recognized by the Jiangsu Province Certification Authority. Among the companies featured is Suzhou RocRock No.1 Biotechnology Co., Ltd., which has now been officially designated as a "High-tech Enterprise".
National High-Tech Enterprise designation is a prestigious accreditation at the national level, awarded to companies that are registered in China for over a year and are actively involved in R&D as well as the commercialization of technological advancements within sectors prioritized by the state. These companies must also possess and operate based on their own core intellectual property rights. Upon receiving this recognition, RocRock Biotech will gain access to a suite of incentives, such as tax relief, fiscal backing, enhanced deductions for research and development expenditures, improved brand value, support for projects, and financial assistance.
RocRock Bio, since its inception, has championed innovation as a driving force for progress, steadfastly focusing on leveraging technological advancements to enhance macrophage therapies for solid tumors. The company has consistently placed R&D innovation at the heart of its growth strategy. By boosting investment in research and development, recruiting top-tier talent, and enhancing collaborations between industry and academia, RocRock Bio has successfully achieved multi-centric clinical translations. Its proprietary CAR-M production encompasses four core technology platforms, bolstered by 58 proprietary intellectual property rights, which solidify the company's foundation for sustainable development. As a clinical-stage cell therapy company, RocRock Bio concentrates on the research and development of macrophage-based drug therapies for oncological treatments. In 2023, the company, in partnership with the Affiliated Hospital of Xuzhou Medical University, initiated an Investigator Initiated Trial (IIT) for the RR-M01 pipeline. This trial has involved multiple patient treatments, demonstrating the safety and efficacy of the RR-M01 pipeline, offering renewed hope for the treatment of malignant solid tumors, particularly for recurrent and refractory ovarian cancer. The RR-M01 pipeline is set to conclude patient enrollment and treatment for the final case in October 2024. The pipeline's scope has been expanded to include all solid tumors that are HER2 positive or have low expression levels. It received ethical approval from the Affiliated Hospital of Xuzhou Medical University in early March 2024 and has since treated nearly half of the planned patient cohort, with a goal to complete treatment for 20 patients by 2025. The pancreatic cancer-targeting pipeline received ethical clearance from Peking Union Medical College Hospital in December 2024 and is actively progressing in its clinical IIT. Additionally, clinical trials for prostate cancer and small cell lung cancer are also underway and advancing as planned.
Earning the High-Tech Enterprise designation is a testament to RocRock's innovative prowess and a validation of our company's overall capabilities. Moving forward, RocRock is committed to the philosophy of "innovation as the engine of growth," aiming to bolster our technological innovation framework and sharpen our competitive edge. We are dedicated to advancing scientific and technological innovation in tandem with industrial progress, and we are proud to contribute to the nation's endeavor to become a leader in innovation.
0512-67998889(Suzhou)
18051093220(Shenzhen)
Cathy.Lv@rocrockbio.com(Suzhou)
lliangjing@rocrockbio.com (Shenzhen)